or on the link below. Immune checkpoint inhibitors (ICIs) are shown to be effective among patients with metastatic colorectal cancer (mCRC) harboring high microsatellite instability (MSI-H) and/or ...
The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...
News Medical on MSN
Study offers a practical strategy to enhance effectiveness of immune checkpoint inhibitors
Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.
In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...
A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...
Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint blockade for treatment of non-small cell lung cancer ...
Soldiers of the adaptive immune system, CD8 + T cells are the immune system's primary killers of cancer cells and the main cell type engaged by immune checkpoint blockade therapies. The elevated ...
Immune Checkpoint Blockade (ICB) has reshaped cancer care and can deliver durable remission in malignancies such as melanoma and non-small cell lung cancer.
Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results